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Abstract
Background: The association between ABCC8 gene C49620T polymorphism and type 2 diabetes (T2D) in populations of
diverse ethnic backgrounds has been reported. However, such occurrence in an African population is yet to
be established. This case-control study involving 73 T2D and 75 non-diabetic (ND) patients investigated the
occurrence of this polymorphism among T2D patients in Nigeria and assessed its relationship with body lipids
of patients.
Methods: Demographic and clinical characteristics of patients were collected and lipid profile indices
including total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high density lipoprotein
(HDL) were assayed. Restriction fragment length polymorphism-PCR (RFLP-PCR) was employed to genotype
the ABCC8-C49620T polymorphism using PstI restriction enzyme.
Results: This study revealed significantly (p < 0.05) higher prevalence of the T allele of the ABCC8 gene in T2D
patients (33.1%) compared to ND patients (28.0%). The mutant TT genotype was also higher than the CC and
CT genotypes in T2D patients compared to ND patients but did not show any significant risk (p>0.05) of T2D
for the unadjusted codominant, dominant and recessive models. Following age adjustment, the mutant genotypes (CT
and TT) showed significant (p<0.05) risk of T2D for all the models with the recessive model presenting the greatest risk
of T2D (OR: 2.39, 95% CI: 1.16-4.91, p<0.018). The TT genotype significantly (p<0.05) associated with high level of HDL
and reduced levels of TC, TG and LDL in non-diabetic patients but was not associated with any of the demographic
and clinical characteristics among T2D patients.
Conclusions: ABCC8 C49620T polymorphism showed possible association with T2D marked by predominance of the
mutant TT genotype in T2D patients. However, the relationship between TT genotype and lipid abnormalities for
possible beneficial effect on people suffering from T2D is unclear.
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Background
Diabetes, one of the leading non-communicable diseases
(NCD), has been recognized as an important cause of pre-
mature death and disability globally [1]. According to
WHO, the global prevalence of the disease has risen from
108 million in the 1980s to a current figure of 422 million
[2]. This increasing prevalence is becoming more promin-
ent in middle or low income countries and T2D accounts
for about 90% of all cases of diabetes [1].
T2D is a complex metabolic disease involving defective
carbohydrates and lipids metabolism. This disease is
characterized by high level of blood glucose due to
impaired secretion of insulin and/or insulin resistance
[3]. The principal role of insulin is to promote glucose
uptake from blood or intercellular spaces into skeletal
muscle cells and adipocytes or for transportation to
other cells where glucose is needed [4]. Normally,
* Correspondence: engwagodwill@gmail.com; gengwa@gouni.edu.ng
1Biochemistry, Department of Chemical Sciences, Godfrey Okoye University,
P.M.B 01014, Thinkers Corner, Enugu, Nigeria
7Department of Biotechnology, Ebonyi State University, P.M.B. 53, Abakaliki,
Nigeria
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Engwa et al. BMC Medical Genetics  (2018) 19:78 
https://doi.org/10.1186/s12881-018-0601-1
pancreatic β-cells constantly synthesize insulin irrespect-
ive of the levels of blood glucose. Insulin, stored within
vacuoles of β-cells is only secreted in response to ele-
vated blood glucose levels. The secretion of insulin is
controlled by the ATP-sensitive potassium (KATP) chan-
nel. This channel consists of four pore forming subunits
of Kir6.2 along with four sulfonylurea receptor (SUR)
subunits [5]. SUR1 is the site where sulfonylurea pro-
teins bind to trigger insulin secretion and it is coded by
the ATP binding cassette, subfamily C, member 8
(ABCC8) gene.
The ABCC8 gene was identified as the locus for familial
persistent hyperinsulinaemic hypoglycaemia of infancy, an
autosomal recessive disorder characterized by unregulated
insulin secretion [6]. Polymorphisms in the ABCC8 gene
has been associated with insulin response in Mexican
American subjects [7] and T2D in French Canadians [8],
but not in a Scandinavian cohort [9]. The C49620T variant
of the ABCC8 gene is the most common polymorphism
found to be associated with T2D [10]. Though association
between C/T polymorphism of ABCC8 gene on exon16–3
(rs1799854) has been shown to be associated with T2D in
many populations groups [11], this association in people
from African ethnic background living with T2D has not
been established. Therefore, this study investigated the as-
sociation of C49620T polymorphism of the ABCC8 gene
with T2D and body lipids in a Nigerian population.
Methods
Study population and design
This study is part of a case-control study that recruited
T2D patients and patients without diabetes (ND) who are
30 years old or above visiting Enugu State University
Teaching Hospital (ESUTH), Enugu Nigeria. Patients con-
sidered as T2D patients were diagnosed according the IDF
criteria [12] with at least 1 year history of diabetes. Non-
diabetic control patients were those without T2D or
hyperglycaemia. Participants included in the study were
without any critical health condition or complications of
diabetes and were not on hospital admission. Women
who are breastfeeding or pregnant as well as HIV positive
patients were excluded from the study. The sample size
(n) was calculated according to Charan and Biswas [13]
using the formula: n ¼ 2SD2 ðZa=2þZBÞ2
d2
¼ 74:19.
Where; SD = standard deviation, Za/2 = Zscore for type
1 error of 5%, ZB = Zscore at 95% power and d = Effect
size from previous study [14]. Thus, 74 participants were
recruited for each arms (case and controls) making a
total of 148 participants.
Ethical considerations
The study was conducted in accordance with the Helsinki
Declaration. Before the commencement of study, ethical
clearance was obtained from ESUTH ethics committee
(Approval No: ESUTHP/C-MAC/RA/034/174). Written
informed consent was obtained from all patients before
participation in the study.
Data collection and biochemical analyses
Following recruitment, participants were administered a
research questionnaire which sought relevant demo-
graphic information including age, sex, ethnicity, location
and disease history. Systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were measured using an auto-
matic sphygmomanometer. In addition, anthropometric
parameters including body weight, height and waist cir-
cumference (WC) of participants were measured. Weight
and height of participants were used for the estimation of
Body Mass index (BMI) as weight (Kg)/ height2 (m2).
Fasting blood glucose (FBG) was measured from whole
blood using an Accucheck glucometer [15]. Total choles-
terol (TC), low density lipoprotein (LDL), triglyceride (TG)
and high-density lipoprotein (HDL) were measured in
serum using commercially available kits (Randox Labora-
tories Ltd., United Kingdom) following the manufacturer’s
recommended protocol. TC was determined according to
the enzymatic method of Allain and collaborators [16], TG
was determined by the enzymatic method of Esders and
Michira [17] and HDL by the precipitation method of
Grove [18]. LDL was estimated using the Freidwald’s
formula: LDL =TC- (TG/5) – HDL [19].
Molecular genotyping of ABCC8 C49620T variant
DNA was extracted using the GeneJET Genomic DNA
Purification kit (K0721) by Thermo Fisher Scientific Inc.,
USA following the manufacturer’s recommended proced-
ure. The ABCC8 C49620T (rs1799854) gene was ampli-
fied in a PCR reaction as previously reported by He et al.
[20], using primers with the following sequences; Forward
- 5’-TTGGGTGCATCTGTCTGTCTGTCTTT-3′ and
Reverse: 5’-AGCCCACCTGCCCCACGAT-3′. The PCR
mix contained 8 μl of genomic DNA (< 10 ng), 12 μl of
taq quick-load 2× master mix (New England Biolab (NEB)
, USA) and 4 μl of 50 μM of each primer. The PCR condi-
tion includes an initial denaturation at 94 °C for 5 min
followed by 35 cycles of denaturation at 94 °C for 20s,
annealing at 62 °C for 40s and extension at 72 °C for 40s
with the final extension at 72 °C for 8 min. The 122 bp
amplicon of ABCC8 was visualised on 2% agarose gel
(100 V for 20 min). Restriction digestion was achieved
using 10 U PstI restriction enzyme (1ul, New England
Biolabs, USA) for 6 h at 37 °C. Restriction fragments were
resolved on a 3% agarose gel stained with ethidium brom-
ide and visualized under UV light. The C49620 allele was
cleaved into 88 and 34 bp restriction fragments, but
T49620 allele remains uncleaved (122 bp).
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Statistical analysis
Data was analyzed using Statistical Package for Social
Sciences (SPSS) version 16. Anthropometric, FBG and lipid
profile data were expressed as frequencies or mean ±
Standard Error of the Mean (S.E.M). Parametric independ-
ent sample t-test was used to compare mean differences of
the lipid profile data and baseline study parameters for the
various ABCC8 C/T genotypes of participants. Pearson
chi-square (χ2) test was used to test for the Hardy-
Weinberg equilibrium by comparing genotype and allele
frequencies in the diabetic and non-diabetic subjects.
Binary and multinomial logistic regression were used to de-
termine the odd ratio (OR) by comparing allele and geno-
type frequencies between diabetic and non-diabetic patients.
A confidence interval of 95% was taken and a p-value less
than 0.05 was considered statistically significant.
Results
In total, 73 T2D patients and 75 ND patients were
recruited for the study. The demographic and clinical
characteristics of the study population are summarized in
our previous publication [21]. As summarized in Table 1,
all 148 samples were successfully amplified for ABCC8
C49620T gene fragment with molecular size of 122 bp
(Fig. 1a). Following restriction digestion, the expected
product sizes were DNA fragment of 88 and 34 bp for nor-
mal homozygote CC genotype, fragments with 122 and
88 bp for a heterozygote CT genotype and an uncleaved
band with size 122 bp for the mutant homozygote TT
genotype (See Fig. 1b). The 34 bp was not seen on the gel.
The mutant T allele was significantly (p < 0.05) predomin-
ant in both the ND and T2D patients than the wild C
allele. Moreover, the prevalence of the T allele was greater
in the T2D patients (33.1%) compared with their ND
counterparts (28.0%). The homozygote CC and heterozy-
gote CT genotypes were more prevalent in ND patients
compared with T2D patients while the homozygote mu-
tant TT genotype showed greater prevalence in T2D pa-
tients compared to ND patients. The CT genotype was not
associated with T2D risk (p>0.05) while the TT genotype
was associated with risk of T2D (OR: 2.58, 95% CI: 1.15-5.
77, p<0.0021) when compared with the CC genotype after
adjusting age. The distribution of the genotype frequencies
between T2D patients and ND patients did not violate the
Hardy-Weinberg equilibrium (χ2 = 2.78; p = 0.249).
To determine the model that predicts the greatest risk
(OR) of T2D, the codominant, dominant and recessive
models were evaluated as shown in Table 2. The codom-
inant model (CC vs. CT vs. TT) showed no significant
risk of T2D (OR: 0.56 (0.27-1.17, p = 0.311) with the CT
and TT genotypes compared along with CC genotype.
The dominant model (CC vs. CT + TT = XT) with the T
allele carriers (XT genotype) did not shown any signifi-
cant risk of T2D when compared with the CC genotype
(OR: 1.60, 95% CI: 0.79-3.23, p = 0.191). Similarly, the re-
cessive model (CX = CC + CT vs. TT) did not show any
significant risk of T2D when the TT genotype was com-
pared to the CX genotype (OR: 1.73, 95% CI: 0.90-3.33,
p = 0.098). However, following age adjustment, the mu-
tant genotypes (CT and TT) showed significant risk
(p<0.05) of T2D for all the models; the codominant,
dominant and recessive models with the recessive model
presenting the greatest risk (OR: 2.39, 95% CI: 1.16-4.91,
p = 0.018) as shown in Table 2.
The relationship of ABCC8 (C/T) polymorphism with
demographic and clinical characteristics of participants
is summarized in Table 3. Comparison of ABCC8 C/T
genotypes (CC, CT, TT) did not show any significant dif-
ferences (p>0.05) on the anthropometric parameters
(BMI and WC) of patients. The levels of FBG and lipid
profile parameters (TC, TG and LDL) were not signifi-
cantly different (p>0.05) among the various genotypes
(CC, CT and TT) in the study population. However,
HDL was significantly higher in patients with the mutant
homozygote TT genotype (p = 0.005). To confirm the
above finding, the relationship between ABCC8 (C/T)
polymorphism with demographic and clinical character-
istics was further assessed separately among T2D
Table 1 Association of ABCC8 C/T alleles and genotypes in participants
ABCC8 C/T variant T2D (%) patients ND (%) patients OR (95% CI) p-value
Allele C 48 (16.2) 67 (22.6) –
T 98 (33.1) 83 (28.0) 1.7 (1.06-2.73) 0.028
Total (2 N) 146 (49.3) 150 (50.7)
Genotype CC 19 (12.8) 27 (18.2) –
CT 10 (6.8) 13 (8.8) 1.09 (0.39-3.01)
1.26 (0.44-3.60)a
0.863
0.668a
TT 44 (29.7) 35 (23.6) 1.79 (0.86-3.73)
2.58 (1.15-5.77)a
0.122
0.021a
Total (N) 73 (49.3) 75 (50.7)
The results showed significant differences (p< 0.05) in allelic and genotypic frequencies between the T2D and ND patients after adjusting for age
OR odd ratio OR, CI confidence interval, N number of participants
aIndicates age adjustments of study participants
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patients as well as ND patients as summarized in
Table 4. Among non-diabetic patients, TC, TG and
LDL levels were significantly lower (p < 0.05) while
HDL was significantly higher (p < 0.005) in patients
with the mutant TT genotype compared to the CT
and TT genotypes. On the other hand, there were no
significant differences (p > 0.05) of demographic and
clinical characteristics for the various genotypes (CC,
CT and TT) among type 2 diabetes patients.
Discussion
Insulin resistance, insulin secretion and obesity are the
most prevalent underlying causes of T2D and thus, much
interest has been to identify potential related genes involved
and possible mutations that may confer susceptibility to the
disease. Polymorphisms of the ABCC8 gene which encodes
SUR1, a surface receptor for sulfonylurea that regulates in-
sulin secretion, has been investigated with much concern
on the C49620T variant which has shown to be associated
with T2D [22]. Our study showed predominance of the T
allele over the C allele with a significant risk (p < 0.05) of
T2D. This is in contrast to findings from other regions
across the globe where the wild type C allele is usually
predominant in the population [23, 24]. The homozygote
mutant TT genotype was more frequent than the homozy-
gote wild type CC genotype while the heterozygote CT was
the least frequent. The TT genotype was more frequent in
T2D patients compared with their ND counterparts and
a
b
MWM D01 D02 D03 D04 D05 D06 D07
122bp
MWM D01 D02 D03 D04 D05 D06 D07
88bp
122bp
Fig. 1 RFLP-PCR of ABCC8 C49620T Polymorphism. a shows the presence of the amplified gene for D01-D07 at 122 bp. b shows the restriction
digest products of the gene. A 122 bp indicates the T allele while a 88 bp indicates the C allele. Sample D01 and D03-D07 show the presence of
the wild-type homozygote CC genotype while D02 shows the presence of the heterozygote CT genotype. MWM indicates 100 bp molecular
weight marker
Table 2 Association of ABCC8 C/T genotypes in participants based on risk models
ABCC8 C/T genotypes T2D (%) patients ND (%) patients OR (95% CI) p-value
Codominant model CC 19 (12.8) 27 (18.2) –
CT 10 (6.8) 13 (8.8) –
(CC vs. CT vs. TT) TT 44 (29.7) 35 (23.6) 0.56 (0.27-1.17)
1.04 (1.01-1.07)a
0.311
0.009a
Dominant model (TX) CC 19 (12.8) 27 (18.2) –
(CC vs. CT + TT = XT) TT + CT 54 (36.5) 48 (32.4) 1.60 (0.79-3.23)
2.13 (1.00-4.52)a
0.191
0.05a
Recessive model (CX) CC + CT 29 (19.6) 40 (27.0) –
(CX = CC + CT vs. TT) TT 44 (29.7) 35 (23.6) 1.73 (0.90-3.33)
2.39 (1.16-4.91)a
0.098
0.018a
Total (N) 73 (49.3) 75 (50.7)
The results showed significant differences (p< 0.05) in genotype frequencies between the T2D and ND patients after adjusting for age for all models
OR odd ratio OR, CI confidence interval, vs. versus, N number of participants
aIndicates age adjustments of study participants
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vice versa for the CC genotype. When the mutant geno-
types (TT, TT +CT) were compared with the CC genotype
between T2D patients and ND patients, there was no sig-
nificant risk (p < 0.05) of T2D for the dominant, codomi-
nant and recessive models. However, when these models
were adjusted for age, the risk of the mutant genotype to
cause T2D was significant (p< 0.05). This result suggests
that the mutant genotypes TT and CT have possible risk of
predisposing people to T2D. This finding is consistent with
previous reports on the association between ABCC8 C/T
polymorphism and T2D [25, 26] as well as the association
between this polymorphism and gestational diabetes [27]
together with the attendant effects on insulin secretion [7,
8]. However, this study is in contrast to a large-scale associ-
ation studies which showed no association of the poly-
morphism with T2D [28]. The recessive model predicted
the greatest risk for T2D and suggests that the mutant TT
genotype is the most vulnerable genotype with a greaterrisk
of T2D than the CT and CC genotypes. The distribution of
genotypes between T2D patients and ND patients did not
violate the Hardy-Weinberg equilibrium in this study
(χ2 = 2.781; p = 0.249), thus the population under con-
sideration was stable.
Since insulin has diverse functions in the body regulat-
ing carbohydrates and lipids by stimulating lipid synthe-
sis from glucose and prevents lipid degradation or
lipolysis [29], we evaluated the relationship between the
ABCC8 C/T polymorphism with obesity, cholesterol, tri-
glyceride and lipoproteins. Findings from our study
showed no significant differences (p> 0.05) of these ge-
notypes (CC, CT and TT) with anthropometric or obes-
ity parameters (BMI, WC), FBG and serum lipids (TC,
TG and LDL) in the study population. This confirms
findings of previous studies which also showed no asso-
ciation of this polymorphism with anthropometric
parameters [23], obesity and body fat [22]. However,
HDL level was significantly higher (p < 0.05) in patients
with the TT genotype compared to those with CT and
CC genotypes in the study population. Further compari-
son of the clinical and demographic characteristics on
the various genotypes (CC, CT and TT) among non-
diabetic patients, showed TC, TG, LDL to be signifi-
cantly lower (p < 0.05) while HDL was significantly
higher (p < 0.05) in patients with the mutant TT geno-
type. If similar finding is observed for T2D patients, it
may suggest that the TT genotype may improve the
HDL level as well as reduce TC, TG and LDL levels in
patients, thereby improving lipid abnormalities which
may be beneficial to T2D as HDL is known to play es-
sential role in the removal of free cholesterol from blood
thereby reducing T2D susceptibility [30]. However, no
significant differences (p > 0.05) were observed for the
demographic and clinical characteristics among type 2
diabetes patients. Thus, it is not yet conclusive to
propose that TT genotype may improve the diabetic sta-
tus of patients by reducing lipid abnormalities as such
finding was not observed among type 2 diabetes patients
Table 3 Relationship of ABCC8 (C/T) polymorphism with
demographic and clinical characteristics of participants
CC genotype CT genotype TT genotype p-value
Age (year) 55.98 ± 2.16 53.57 ± 2.56 50.84 ± 1.62 0.148
WC (cm) 94.19 ± 2.66 97.00 ± 4.02 94.75 ± 1.99 0.836
BMI (Kg/m2) 29.24 ± 1.51 28.73 ± 1.25 30.05 ± 1.15 0.818
FBG (mg/dl) 119.69 ± 15.59 97.43 ± 12.28 118.92 ± 9.36 0.545
TC (mg/dl) 185.46 ± 20.52 217.42 ± 19.75 247.78 ± 25.75 0.206
TG (mg/dl) 192.12 ± 11.49 220.36 ± 18.23 187.64 ± 15.09 0.470
LDL (mg/dl) 118.61 ± 20.64 132.02 ± 20.71 161.90 ± 26.39 0.460
HDL (mg/dl) 36.11 ± 2.47 41.88 ± 3.98 57.38 ± 5.23 0.005
Results showed a significantly higher (p < 0.05) HDL-c level in patients with TT
genotype. Results are expressed as mean ± S.E.M
S.E.M standard error of the mean, WC waist circumference, BMI body mass
index, FBG fasting blood glucose, TC total cholesterol, TG triglyceride, LDL low
density lipoprotein, HDL high density lipoprotein
Table 4 Comparison of ABCC8 (C/T) polymorphism with demographic and clinical characteristics among T2D and ND patients
Type 2 Diabetes patients Non-Diabetic patients
CC genotype CT genotype TT genotype p-value CC genotype CT genotype TT genotype p-value
Age (year) 58.67 ± 2.37 61.50 ± 2.59 55.05 ± 1.55 0.128 54.19 ± 3.22 47.46 ± 3.19 45.53 ± 2.89 0.111
WC (cm) 103.12 ± 2.89 104.00 ± 2.50 98.32 ± 2.37 0.342 88.12 ± 3.56 90.70 ± 6.86 89.94 ± 3.26 0.608
BMI (Kg/m2) 32.74 ± 3.09 29.31 ± 1.86 31.29 ± 1.83 0.764 26.82 ± 1.25 28.25 ± 1.76 28.46 ± 1.16 0.909
FBG (mg/dl) 203.99 ± 27.91 150.30 ± 13.73 153.19 ± 13.35 0.128 60.37 ± 3.18 56.77 ± 7.96 73.94 ± 7.26 0.146
TC (mg/dl) 259.88 ± 43.84 235.58 ± 10.16 318.20 ± 43.86 0.516 135.84 ± 10.65 203.46 ± 34.17 161.27 ± 5.29 0.010
TG (mg/dl) 224.97 ± 15.33 286.25 ± 19.69 237.82 ± 23.97 0.482 170.22 ± 14.96 169.68 ± 19.01 124.55 ± 7.51 0.010
LDL (mg/dl) 183.44 ± 46.36 141.22 ± 11.43 241.07 ± 44.22 0.445 75.39 ± 9.25 124.93 ± 36.14 64.64 ± 6.64 0.010
HDL (mg/dl) 31.12 ± 4.36 38.31 ± 7.02 33.46 ± 2.62 0.612 39.43 ± 2.81 44.63 ± 4.66 87.45 ± 9.11 <0.0001
Results showed a significantly (p < 0.05) lower TC, TG, LDLand higher HDL levels in non-diabetic patients with TT genotype. Results are expressed
as mean ± S.E.M
S.E.M standard error of the mean, WC waist circumference, BMI body mass index, FBG Fasting blood glucose, TC total cholesterol, TG triglyceride, LDL low density
lipoprotein cholesterol, HDL high density lipoprotein cholesterol
Engwa et al. BMC Medical Genetics  (2018) 19:78 Page 5 of 7
in this study. Further detailed studies are needed to bet-
ter explain or confirm the association of ABCC8 C/T
polymorphic genotypes with T2D as well as body lipids
taking into consideration that the sample size of this
study may be limiting to make generalized conclusions.
Conclusion
This study revealed possible association of ABCC8
C49620T polymorphism with T2D marked by predomin-
ance of the mutant T allele and TT genotype in T2D pa-
tients. However, the relationship between TT genotype
and lipid abnormalities for possible beneficial effect on
people suffering from T2D is not clear. Thus, further
studies are needed to further investigate this possibility.
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